Tests for growth hormone secretion

Str.—We were interested in the correspondence between Dr Addy and Professor Brook and Dr Hindmarsh on detecting organic illness through assessment of height velocity.1 2 The question, however, is academic and their arguments theoretical, since we have recently shown, the assessment of height velocity in individuals is so imprecise as to be clinically meaningless. There is effectively no correlation between successive velocities, so that a 12 month velocity cannot possibly identify anyone.3 4

The Wessex Growth Study provides a practical demonstration of the problem. Thirty (17%) of the original cohort of 174 school entrants below the third height centile had identifiable organic disease. Eighteen of these were monitored over a period of three years alongside a cohort of 78 short ‘normal’ children in whom all pathology had been excluded. The height velocity of four of the short ‘normal’ children and two of those with organic disease was deemed to be on or below the third centile for velocity after the first year. Over the next 12 months, two of the short ‘normal’ subjects, and three of those with organic disease, were growing at a rate below the third centile, but the identity of the ‘poor growers’ changed from year one to year two.

We should abandon the notion that low 12 month velocities will effectively identify pathology. The children in the Wessex Growth Study with organic causes of short stature were identified at the beginning of year one on the basis of height screening alone.

L D Voss
The Wessex Growth Study, Room CD53, Southampton General Hospital, Southampton SO9 4XY


Mr Bailey and Ms Voss comment: Professor Healy is right to stress that velocity could, in some cases, be a useful discriminator in a screening context, but in our paper we were concerned mainly with the estimation of height velocities, and we showed that the imprecision attached to these estimations can be considerable. Unfortunately, disease-specific growth charts are rare and more are needed. In the case of Turner’s syndrome such a chart is available and the mean velocity is shown to be lower than normal.1 2 If one were to screen for the disease by identifying all girls with a velocity less than the 3rd centile on the normal velocity chart, between the ages of 5-6 years, this would locate about 25% of girls with Turner’s syndrome. On the other hand, screening for those below the 3rd centile for height, using the normal height chart at age 5 years, would pick out over 50% of these girls. (Actually, screening by height and then by velocity would be even better as girls with Turner’s syndrome are on average shorter than normal and they also fall further behind with increasing age. As Professor Healy points out, however, the extra information gained may not be worth the delay involved.)

The problem of choosing an appropriate method of screening is further demonstrated by our letter in this issue regarding the comments of Dr Addy.3 In this, we describe how children in the Wessex Growth Study with pathology could not be distinguished from healthy children by their velocity over a single 12 month period. Certainly much work is yet to be done, and data collected on a variety of organic diseases, before it is possible to evaluate rival screening methodologies.


Terbutaline powder in asthma exacerbations

Str.—Inhaled b2 agonists are the most efficient means of relieving acute bronchoconstriction in asthmatic children. However, inhalation technique with a metered dose inhaler is often unsatisfactory particularly in young dyspnoeic children. Spacers have been shown to be useful in this setting.1 2 Asthmatic children may be reluctant to carry spacers during daily activities because they are cumbersome. The Turbuhaler (Astra, Turbuhaler in the UK) is a new multidose breath actuated pure powder inhaler available for the administration of terbutaline. It can be triggered by an airflow of 22 l/min, this is reached by almost all children over 5 years old in a stable condition and even by those with moderately acute asthma.3 Terbutaline given with a Turbuhaler is effective in the treatment of exercise induced asthma.4 It has not been reported yet if terbutaline with Turbuhaler is effective in children with acute asthma.

Twenty two children attending the hospital with acute wheeze were included in an open, randomised, parallel group study comparing the efficacy of 0·5 mg of terbutaline given either with a Turbuhaler or with a metered dose inhaler attached to Nebulizer (Astra). Administration of the drug was carefully supervised and consisted of one inhalation by the Turbuhaler or two consecutive puffs of terbutaline introduced separately by the Nebulizer at one minute intervals as previously described.5 6 Before, 15 and 30 minutes after treatment we measured specific airway resistance (sRaw in cm H2O/l/s, body plethysmograph 2800, Physiosystem), forced expiratory velocity (FEV1, ml/s), peak expiratory flow (PEFR, l/min).

Results in efficacy of the two systems after inhaling 500 µg of terbutaline. Results are mean (SD)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Nebulizer</th>
<th>Turbuhaler</th>
</tr>
</thead>
<tbody>
<tr>
<td>sRaw (cm H2O/l/s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial</td>
<td>14±1 (3-5)</td>
<td>13±3 (3-4)</td>
</tr>
<tr>
<td>15 Minutes</td>
<td>7±4 (2-0)</td>
<td>6±4 (1-6)</td>
</tr>
<tr>
<td>30 Minutes</td>
<td>6±3 (1-7)</td>
<td>6±4 (1-9)</td>
</tr>
<tr>
<td>FEV1 (ml/s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial</td>
<td>1200 (290)</td>
<td>1610 (510)</td>
</tr>
<tr>
<td>15 Minutes</td>
<td>1550 (380)</td>
<td>1820 (580)</td>
</tr>
<tr>
<td>30 Minutes</td>
<td>1560 (600)</td>
<td>1830 (580)</td>
</tr>
<tr>
<td>PEFR (l/min)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Initial</td>
<td>184 (47)</td>
<td>217 (74)</td>
</tr>
<tr>
<td>15 Minutes</td>
<td>214 (56)</td>
<td>265 (75)</td>
</tr>
<tr>
<td>30 Minutes</td>
<td>253 (54)</td>
<td>276 (85)</td>
</tr>
</tbody>
</table>
The reliability of height and height velocity in the assessment of growth.

M J Healy

Arch Dis Child 1991 66: 1465
doi: 10.1136/adc.66.12.1465-a

Updated information and services can be found at:
http://adc.bmj.com/content/66/12/1465.2.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/